Search

Your search keyword '"Ancona, C"' showing total 459 results
Start Over Author "Ancona, C"
459 results on '"Ancona, C"'

1. Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models

Author

Becattini, Cecilia, Gulizia, Michele M., Agnelli, Giancarlo, Dentali, Francesco, Di Lenarda, Andrea, Enea, Iolanda, Fabbri, Andrea, Maggioni, Aldo P., Pomero, Fulvio, Ruggeri, Maria Pia, Lucci, Donata, Vedovati, Maria Cristina, Duranti, Michele, Guercini, Francesco, Groff, Paolo, Verso, Melina, Fabbri, Gianna, Savoia, Martina, Baldini, Ester, Mecatti, Barbara Bartolomei, Bianchini, Francesca, Ceseri, Martina, Gonzini, Lucio, Gorini, Marco, Lorimer, Andrea, Orsini, Giampietro, Tricoli, Martina, Cimini, L.A., Becattini, C., Agnelli, G., Cesarini, V., Sanna, M., Pepe, G., Marchetti, C., Roldan, M. Olivan, Lenzi, L., Cozzio, S., Tomio, P., Diamanti, M., Beltrame, A., Glinski, L., Treleani, M., Coppa, A., Vanni, S., Bartalucci, P., Taccone, A., Costacurta, C., Bortolotti, P., Bortolussi, M., De Vecchi, M., Zanardi, F., Greco, I., Cosentini, R., Gerloni, R., Artusi, N., Cominotto, F., Sisto, U.G., Picariello, C., Roncon, L., Maddalozzo, A., Nitti, C., Riccomi, F., Buzzo, M., Bassanelli, G., Savonitto, S., Bianchi, A., Bilato, C., Lobascio, I., Dalla Valle, C., Pomata, D.P., Giostra, F., Tinuper, A.L., Zalunardo, B., Visonà, A., Panzavolta, C., Novelli, A., Bertini, A., Granai, C., Colombo, S., Periti, E., Bonacchini, L., Abrignani, M.G., Casciolo, M.F., D'Amato, A., Scardovi, A.B., Ricci, R., Iosi, S., Fontana, M.C., Marrazzo, A., Borselli, M., Di Fusco, S.A., Colivicchi, F., Enea, I., Triggiani, M., Papa, I., Pasini, G.F., Fioravanti, C., Panarello, S., Raggi, F., Marzolo, M., Cuppini, S., Milan, M., Barchetti, M., De Laura, D., Caldarola, P., Fiorini, R., Rastelli, G., Ameri, P., La Malfa, G., Cinelli, F., Sganzerla, P.C., Ubaldi, S., Sanchez, F.A., Forgione, C., Cuccia, C., Predieri, S., Fusco, S., Mumoli, N., Porta, C., Romei, M., Lucidi, M., Romaniello, A., Volpe, M., Mogni, P., Pizzolato, E., Martino, G.P., Bitti, G., Righini, G., Bandiera, G., Pennacchio, E., Limauro, S., Dachille, A., Ignone, G., Fuscaldo, G.F., De Rosa, F.M., Vazzana, N., Chesi, G., Di Filippo, F., Pierpaoli, L., Corapi, A., Vatrano, M., Angotti, C., Baccetti, F., Harari, S.A., Luisi, F., Daghini, E., De Curtis, E., Lucà, F., Ciancia, F., Blandizzi, S., Lettica, G.V., D'Orazio, S., Cosmi, F., Zaccaroni, S., Silingardi, M., Valeriano, V., Pugliese, F.R., Murgia, A.P., Parpaglia, P. Pinna, Martinelli, L., Caponi, C., Clemente, M.A., Ciccarone, A., Bongarzoni, A., Garagiola, M., Leone, M.C., Veropalumbo, M.R., Sacco, M., Morella, P., Dorigoni, S., Peterlana, D., Di Paola, R., Felis, S., Correale, M., Brunetti, N.D., Petrelli, G., Feliziani, F.T., Mastroiacovo, D., Romualdi, R., Pasin, F., Bonardi, S., Delfino, P., Scifo, C., Savioli, G., Ceresa, I.F., Galeotalanza, M., Benazzi, B., Porzio, M., Rosini, F., Ancona, C., Verrelli, C., Pasini, A. Fratta, Dalle Carbonare, L., Bozza, N., Nacci, F., Scarabelli, M.A., Amico, F., Marchesi, C., Mazzone, A., Di Tommaso, R., Cocco, F., Pezzuto, G., Luciani, A., Zamboni, P., Muriago, M., Del Pesce, L., Lucarini, A.R., Guglielmelli, E., Vannucchi, V., Moroni, F., Fichera, D., Malatino, L., Sgroi, C., Morana, I.M., Cicero, S., La Rosa, D., Mete, F., Gino, M., De Palma, A., Alessandri, M., Maestripieri, V., Battocchio, M., De Santis, M.T., Saladini, F., Corsi, D.C., Macarone Palmieri, N., Pierfranceschi, M. Giorgi, Palmonari, V., Fontanella, L., Airoldi, L., Bonocore, M., Paliani, U., Prat, L. Iogna, Chiecchi, L., Cuonzo, M., Paludo, A., Padula, D., Antonelli, A., Bicchi, M., Tota, G., Ariello, M., Sai, R., Civita, M., Tucci, M., Barbati, G., Conti, M., Cettina, R., Magnani, O., Levato, M., Gessi, V., De Rui, M., Bellizzi, A., Farneti, L., Salomone, P., Mannarini, A., Grifoni, E., Del Ghianda, S., Campodonico, J., De Cesare, N., Mutone, D., Pasoli, P., Meloni, S., Frenda, A., Viola, G., Torromeo, C., Campana, C., Pistone, M.C., Caravita, S., La Creta, C.P., Miscio, F., Loreno, M., Fenu, P., Mazzetti, M., Rossini, D., Brunacci, M., Capuano, A., Tagliamonte, G., Pinelli, M., Ballocca, F., Parca, G., Pasini, S.M., Maragno, M.G., Vecchi, F., Mancinelli, L., Cavalli, A., Di Mare, F., Conficoni, E., Miceli, R., Pecoraro, R., Fonti, C., Pegoraro, S., Piccinni, G.C., Caruso, G., Boriani, G., Lanzillotta, P., Piccolo, P., Calò, L., Stolfo, D., Mangiacapra, S., Marziali, A., Volponi, M.C., Querci, G., Terribile, R., Menabue, M., Fiorentini, A., Musci, R.L., Uras, S., Cicini, M.P., Manetti, S., Francese, G.M., Melchio, R., Scorpiglione, N., Carrara, D., Pani, A., Morisco, C., Rodolico, M., Colombo, Silvia, Vanni, Simone, Abrignani, Maurizio Giuseppe, Scardovi, Angela Beatrice, Marrazzo, Alessandra, Borselli, Matteo, Barchetti, Marco, and Maggioni, Aldo Pietro

Published
2024
Full Text
View/download PDF

2. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Alù, M., Ancona, C., Andreis, D., Bajardi, E., Benedetto, C., Berardi, R., Bordin, E., Butti, C., Capri, G., Cicchiello, F., Cocciolone, V., Dester, M., D'Onofrio, L., Febbraro, A., Ferrarini, I., Fotia, V., Gervasi, E., Guaitoli, G., Licata, L., Liscia, N., Mentuccia, L., Miraglio, E., Nicolini, M., Paternò, E., Pedani, F., Pellegrini, D., Petrucelli, L., De Laurentiis, M., Pizzuti, L., Pogliani, C., Riva, F., Cazzaniga, M.E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G.V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M.C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M.R., Vici, P., Zambelli, A., Clivio, L., and Torri, V.

Published
2017
Full Text
View/download PDF

4. Stereo tests as a screening tool for strabismus: which is the best choice?

Author

Ancona C, Stoppani M, Odazio V, La Spina C, Corradetti G, and Bandello F

Subjects
Ophthalmology, RE1-994
Abstract

Chiara Ancona, Monica Stoppani, Veronica Odazio, Carlo La Spina, Giulia Corradetti, Francesco Bandello Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy Purpose: To compare four stereo tests (Lang I, Lang II, Titmus, and TNO) and assess their effectiveness. The main focus of this study is to identify the most useful stereo test as a challenging tool in the screening of strabismus. Patients and methods: A total of 143 Caucasian subjects, 74 males (52%) and 69 females (48%), aged between 4 years and 78 years (mean age 19.09±15.12 years) were examined at our Strabismus Service (Scientific Institute San Raffaele Hospital, Milan, Italy) and included in this observational cross-sectional study. Subjects recruited in this study were either affected by strabismus, including microstrabismic patients, or healthy volunteers. Subjects affected by ophthalmological diseases, other than strabismus, were excluded. All patients underwent both ophthalmological and orthoptic examination, including stereo tests, Hirschberg Corneal Light Reflex Test, Worth Four-Dot Test, the 4 Prism Diopter Base-Out Test, Cover Testing, ­Bruckner Test, visual acuity, automated refraction under 1% tropicamide cycloplegia and thereafter, posterior pole evaluation. Results: All data were processed using the IBM SPSS Statistics, Version 2.0, to perform all statistical calculations. The main finding of this study is that Lang I stereo test achieved the highest sensitivity (89.8%) and specificity (95.2%) in detecting strabismus, including microstrabismus as well, compared to all the other stereoacuity tests. Furthermore, Lang I is the stereo test with the highest positive predictive value and negative predictive value, both greater than 90%. Conclusion: The stereo test with the highest sensitivity, specificity, positive predictive value, and negative predictive value is Lang I. These results suggest its applicability as a screening test for strabismus in people older than 4 years. Keywords: stereo tests, screening, strabismus, Lang I

Published
2014

5. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, Matteo, Butti, C., Liscia, N., Pogliani, C., Capri, Giorgia, Alu', Matteo, Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, Enrico, Guaitoli, G., Ferrarini, I., Gervasi, Elisea, Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, Anna, Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, Ruggero Astolfo, Clivio, L., Torri, V., Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cazzaniga, M. E, Bianchi, G. V, Cursano, M. C, Valerio, M. R, Torri, V., De Laurentiis, Michelino, Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, E., Guaitoli, G., Ferrarini, I., Gervasi, E., Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Cazzaniga, M., Ala, M., ARRIVAS BAJARDI, E., Paternã², E., Bianchi, G., Cursano, M., and Valerio, M.

Subjects
0301 basic medicine, Oncology, Receptor, ErbB-2, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Dose-intensity, Exemestane, 80 and over, Neoplasm Metastasis, Fulvestrant, Aged, 80 and over, education.field_of_study, Advanced breast cancer, Dose-intensity, Everolimus, Fulvestrant, Hormone-receptor positive, Advanced breast cancer, Everolimus, Hormone-receptor positive, Adult, Aged, Androstadienes, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Surgery, General Medicine, Everolimu, 030220 oncology & carcinogenesis, Receptor, medicine.drug, medicine.medical_specialty, Population, Socio-culturale, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Adverse effect, education, Gynecology, business.industry, fungi, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, business
Abstract

Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33–83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1–7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4–58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). Conclusions The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.

Published
2017

7. Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient

Author

Valerio M. R., Ancona C., Marchese A., Cipolla C., Graceffa G., Gebbia V., Valerio M.R., Ancona C., Marchese A., Cipolla C., Graceffa G., and Gebbia V.

Subjects
trastuzumab, breast cancer, HER-2, metastasis, Nab-paclitaxel
Abstract

Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However the role of late-line treatment in heavily pretreated patients is largely unclear. In the last decade nab-paclitaxel has show significant activity and good toxicity profile in metastatic breast cancer. We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-Tissue. The patients received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.

Published
2020

8. Gastric metastasis from breast cancer

Author

Gebbia V., Bellavia G., Bajardi E. A., Arcara C., Ancona C., Vaccaro G., Cipolla C., Graceffa G., Valerio M. R., Gebbia V., Bellavia G., Bajardi E.A., Arcara C., Ancona C., Vaccaro G., Cipolla C., Graceffa G., and Valerio M.R.

Subjects
stomach metastasis, breast cancer, gastric metastasis
Abstract

Introduction: Breast carcinoma is the most common malignancy in women and the main cause of tumor deaths. Despite early recognition by screening and improvement in treatment regimens, many patients will eventually develop metastases, either locoregional recurrences or distant metastases, most frequently in the skeleton, liver and lung. Metastases to the gastrointestinal tract are infrequent and not even mentioned in the major oncologic textbooks. Case presentation: We report a case of metastasis to the stomach from occult breast cancer. The diagnosis was established by computed tomography (CT), histologic and immunohistochemical analyses of biopsies of the stomach lesion. The patient was treated with pre-operative hormonal therapy, undergoes breast surgery and then treated with systemic chemotherapy. She is still alive 2 years after initial symptoms of dyspepsia. Conclusion: The differentiation between primary gastric cancer and a metastatic breast tumor to the stomach is important for planning of treatment and to spare the patient unnecessary gastric surgery.

Published
2020

10. Challenges to evidence synthesis and identification of data gaps in human biomonitoring

Author

Virgolino, A. Santos, O. Costa, J. Fialho, M. Iavicoli, I. Santonen, T. Tolonen, H. Samoli, E. Katsouyanni, K. Baltatzis, G. Ruggieri, F. Abballe, A. Petrovičová, I. Kolena, B. Šidlovská, M. Ancona, C. Eržen, I. Sepai, O. Castaño, A. Kolossa-Gehring, M. Fiddicke, U.

Abstract

The increasing number of human biomonitoring (HBM) studies undertaken in recent decades has brought to light the need to harmonise procedures along all phases of the study, including sampling, data collection and analytical methods to allow data comparability. The first steps towards harmonisation are the identification and collation of HBM methodological information of existing studies and data gaps. Systematic literature reviews and meta-analyses have been traditionally put at the top of the hierarchy of evidence, being increasingly applied to map available evidence on health risks linked to exposure to chemicals. However, these methods mainly capture peer-reviewed articles, failing to comprehensively identify other important, unpublished sources of information that are pivotal to gather a complete map of the produced evidence in the area of HBM. Within the framework of the European Human Biomonitoring Initiative (HBM4EU) initiative—a project that joins 30 countries, 29 from Europe plus Israel, the European Environment Agency and the European Commission—a comprehensive work of data triangulation has been made to identify existing HBM studies and data gaps across countries within the consortium. The use of documentary analysis together with an up-to-date platform to fulfil this need and its implications for research and practice are discussed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Published
2021

14. Impact of the environment on the health: From theory to practice

Author

Carducci, A.L., primary, Agodi, A., additional, Ancona, C., additional, Angelini, P., additional, Bagordo, F., additional, Barbone, F., additional, Birbaum, L., additional, Carreri, V., additional, Casuccio, A., additional, Conti, A., additional, Conversano, M., additional, De Donno, A., additional, De Giglio, O., additional, Desiante, F., additional, Di Pietro, A., additional, Dogliotti, E., additional, Donato, F., additional, Fara, G.M., additional, Fiore, M., additional, Forastiere, F., additional, Giammanco, G., additional, Izzotti, A., additional, Montagna, M.T., additional, Oliveri Conti, G., additional, Petronio, M.G., additional, Sciacca, S., additional, Signorelli, C., additional, Testai, E., additional, Verani, M., additional, Vinceti, M., additional, Vitale, F., additional, Ferrante, M., additional, Adani, G., additional, Berghella, L., additional, Calia, C., additional, Calzolari, R., additional, Canale, A., additional, Castiglione, D., additional, Copat, C., additional, Cristaldi, A., additional, Cuffari, G., additional, Coronel Vargas, G., additional, De Vita, E., additional, De Nard, F., additional, Federigi, I., additional, Filippini, T., additional, Grasso, A., additional, Leonardi, N., additional, Letzgus, M., additional, Lo Bianco, G., additional, Mazzucco, W., additional, Nicolosi, I., additional, Orlandi, P., additional, Paladino, G., additional, Pizzo, S., additional, Pousis, C., additional, Raffo, M., additional, Rivolta, S., additional, Scarpitta, F., additional, Trani, G., additional, Triggiano, F., additional, Tumbarello, A., additional, Vecchio, V., additional, Zuccarello, P., additional, and Vassallo, M., additional

Published
2021
Full Text
View/download PDF

21. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Author

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L., La Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Torri, V., On behalf of The EVA Study Group, Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, D'Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter, Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, On behalf of The EVA Study, G, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio MR., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M.C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., and On behalf of The EVA Study Group

Subjects
medicine.medical_specialty, Socio-culturale, Hormone-receptor positive, Exemestane, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Elderly, Weight loss, Internal medicine, Advanced breast cancer, Everolimus, Oncology, medicine, 030212 general & internal medicine, Stomatitis, Pneumonitis, business.industry, Cancer, medicine.disease, Rash, Everolimu, chemistry, 030220 oncology & carcinogenesis, MED/06 - ONCOLOGIA MEDICA, medicine.symptom, business, Research Paper, medicine.drug
Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018

23. SENTIERI - Studio epidemiologico nazionale dei territori e degli insediamenti esposti a rischio da inquinamento. Quinto Rapporto [SENTIERI: Epidemiological Study of Residents in National Priority Contaminated Sites. Fifth Report]

Author

Zona, A., Iavarone, I., Buzzoni, C., Conti, S., Santoro, M., Fazzo, L., Pasetto, R., Pirastu, R., Bruno, C., Ancona, C., Bianchi, F., Forastiere, F., Manno, V., Minelli, G., Minerba, A., Minichilli, F., Stoppa, G., Pierini, A., Ricci, P., Scondotto, S., Bisceglia, L., Cernigliaro, A., Ranzi, A., Comba, P., Ferretti, S, Gruppo di lavoro SENTIERI, Gruppo di lavoro AIRTUM-SENTIERI, and Gruppo di lavoro Malformazioni Congenite-SENTIERI

Subjects
residential population, cancer incidence, children, congenital anomalies, health effects, National Priority Contaminated Sites, environmental exposure, mortality, cancer incidence, hospitalization, congenital anomalies, health effects, residential population, children, young adult, surveillance, environmental exposure, surveillance, Socio-culturale, young adult, National Priority Contaminated Sites, mortality, hospitalization
Published
2019

34. HTA & MCDA In The Treatment of Macular Edema

Author

Ferrario, L, primary, Foglia, E, additional, Bandello, F, additional, Ferri, C, additional, Figini, I, additional, Franzin, M, additional, Gambaro, G, additional, Introini, U, additional, Staurenghi, G, additional, Tadini, P, additional, Zuppini, T, additional, Tessari, R, additional, Scarpa, G, additional, Urban, F, additional, Beltramini, S, additional, Tobaldi, RF, additional, Nicolò, M, additional, Ancona, C, additional, Moriconi, S, additional, Nuti, E, additional, Fusco, F, additional, and Croce, D, additional

Published
2017
Full Text
View/download PDF

35. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cazzaniga, M.E., primary, Airoldi, M., additional, Arcangeli, V., additional, Artale, S., additional, Atzori, F., additional, Ballerio, A., additional, Bianchi, G.V., additional, Blasi, L., additional, Campidoglio, S., additional, Ciccarese, M., additional, Cursano, M.C., additional, Piezzo, M., additional, Fabi, A., additional, Ferrari, L., additional, Ferzi, A., additional, Ficorella, C., additional, Frassoldati, A., additional, Fumagalli, A., additional, Garrone, O., additional, Gebbia, V., additional, Generali, D., additional, La Verde, N., additional, Maur, M., additional, Michelotti, A., additional, Moretti, G., additional, Musolino, A., additional, Palumbo, R., additional, Pistelli, M., additional, Porpiglia, M., additional, Sartori, D., additional, Scavelli, C., additional, Schirone, A., additional, Turletti, A., additional, Valerio, M.R., additional, Vici, P., additional, Zambelli, A., additional, Clivio, L., additional, Torri, V., additional, Alù, M., additional, Ancona, C., additional, Andreis, D., additional, Bajardi, E., additional, Benedetto, C., additional, Berardi, R., additional, Bordin, E., additional, Butti, C., additional, Capri, G., additional, Cicchiello, F., additional, Cocciolone, V., additional, Dester, M., additional, D'Onofrio, L., additional, Febbraro, A., additional, Ferrarini, I., additional, Fotia, V., additional, Gervasi, E., additional, Guaitoli, G., additional, Licata, L., additional, Liscia, N., additional, Mentuccia, L., additional, Miraglio, E., additional, Nicolini, M., additional, Paternò, E., additional, Pedani, F., additional, Pellegrini, D., additional, Petrucelli, L., additional, De Laurentiis, M., additional, Pizzuti, L., additional, Pogliani, C., additional, and Riva, F., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results